INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Schedule of Components of Pre-tax Loss

The following table sets forth the components of the Company's loss before income taxes by country (in thousands):

	Year Ended December 31,
	2022		2021		2020
Country
United States	$	(37,289)	$	(32,757)	$	(35,529)
Canada	13,530		24,148		14,577
Total Loss Before Income Taxes	$	(23,759)	$	(8,609)	$	(20,952)

Schedule of Components of Income Tax Benefit (Provision)

The Company's tax benefit (provision) is comprised of the following components (in thousands):

	Year Ended December 31,
	2022		2021		2020
Current Tax Provision
Federal	$	—	$	—	$	—
State	—		—		—
Foreign	(94)		(286)		(1,445)
Total current (provision)	$	(94)	$	(286)	$	(1,445)
Deferred tax provision
Federal	$	—	$	—	$	—
State	—		—		—
Foreign	3,969		8,559		—
Total deferred benefit (provision)	$	3,969	$	8,559	$	—
Total Tax Benefit (Provision)	$	3,875	$	8,273	$	(1,445)

Reconciliation of Expected Income Tax Expense

The following table sets forth a reconciliation of the statutory United States federal income tax rate to the Company’s effective income tax rate:

	Year ended December 31,
	2022		2021		2020
United States federal statutory income tax rate	21.0	%	21.0	%	21.0	%
Impact of foreign rate differential	(3.3)		(15.9)		(4.2)
State taxes, net of federal benefit	0.9		2.3		2.0
Stock option cancellations	—		(1.1)		(0.2)
Contingent consideration	59.1		178.2		14.4
General business credits and other credits	0.5		2.4		6.6
Goodwill write-off	(14.8)	%	—	%	—	%
Permanent differences	(1.9)		(1.4)		0.2
Other	(0.2)		(13.8)		(2.1)
Foreign taxes	—		(3.3)		(6.9)
Change in valuation allowance	(44.6)		(72.3)		(37.7)
Effective Income Tax Rate	16.7	%	96.1	%	(6.9)	%

Schedule Components of Deferred Tax Liabilities

The following table sets forth the tax effects of temporary differences that gave rise to significant portions of the Company's deferred tax assets and liabilities (in thousands):

	December 31,
	2022		2021		2020
Deferred tax assets:
NOL carryforwards	$	66,374	$	63,381	$	57,935
R&D credit carryforwards	4,489		4,316		3,787
IRC 174 Capitalized R&D	6,214		—		—
Accruals and other	5,326		4,058		3,811
Capitalized start-up costs	34		53		70
Other	16		41		28
Gross deferred tax assets	82,453		71,849		65,631
Deferred tax liabilities:
IPR&D	—		(3,969)		(12,528)
Gross deferred tax liabilities	—		(3,969)		(12,528)
Valuation allowance	(82,453)		(71,849)		(65,631)
Net Deferred Tax Liability	$	—	$	(3,969)	$	(12,528)

Schedule of Credit Carryforwards

The following table summarizes the Company's NOL and R&D and other credit carryforwards in the United States and Canada as of December 31, 2022 (in millions):

	Amount		Expiration Beginning in	Through
United States:
Federal NOL carryforwards - indefinite	$	101.2	None	None
Federal NOL carryforwards	$	117.7	2030	2038
State NOL carryforwards	$	138.4	2030	2041
Federal R&D credit carryforwards	$	2.6	2027	2041
State R&D credit carryforwards	$	0.9	2027	2041
Canada:
Federal non-capital loss carryforwards	$	43.2	2035	2041
Federal scientific research and experimental development           expense carryforwards	$	5.1	2032	2041
Federal and provincial investment tax credit carryforwards	$	1.2	2032	2041